Literature DB >> 2368170

High prevalence of occult papillary thyroid carcinoma in a surgical series for benign thyroid disease.

M R Pelizzo1, A Piotto, D Rubello, D Casara, A Fassina, B Busnardo.   

Abstract

In a surgical series of 277 consecutive patients operated on the thyroid for benign diseases, a high prevalence rate (10.5%) of occult papillary carcinoma was found by means of an accurate histologic examination. Indications for surgery were euthyroid multinodular goiter in 25 patients, autonomously hyperfunctioning adenoma in 2 and Graves' disease in 2 patients. Neoplastic foci were unilaterally found in 25 cases but multifocally in 6 and bilaterally in 4 cases: the diameters ranged from 2-10 mm. After operation (14 subtotal and 15 total thyroidectomies), all patients received TSH-suppressive doses of T4. At a mean follow-up of 5.6 years, neither local recurrences nor lymph node or distant metastases had occurred; no patient died of the tumor. In keeping with other surgical and autopsy series, the prevalence of occult thyroid carcinoma in a normal population is calculated to be about 5-10%, whereas it is known that the prevalence of clinically evident thyroid cancer is only 0.05%. This means that only 1-2% of occult carcinomas may evolve in an overt tumor during life. In view of such an epidemiologic difference and the favorable course of our patients, although the mean follow-up is rather short, we suggest that lobectomy plus T4 treatment may be considered an adequate therapeutic approach in patients with occult papillary thyroid carcinoma.

Entities:  

Mesh:

Year:  1990        PMID: 2368170     DOI: 10.1177/030089169007600309

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  11 in total

1.  Total versus hemithyroidectomy for microscopic papillary thyroid cancer.

Authors:  M Gershinsky; O Barnett-Griness; N Stein; D Hirsch; G Tzvetov; O Bardicef; J Pauker; S Grozinsky-Glasberg; S Ish-Shalom; I Slutski; I Shimon; C Benbassat
Journal:  J Endocrinol Invest       Date:  2011-09-27       Impact factor: 4.256

2.  A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma.

Authors:  Leo A Niemeier; Haruko Kuffner Akatsu; Chi Song; Sally E Carty; Steven P Hodak; Linwah Yip; Robert L Ferris; George C Tseng; Raja R Seethala; Shane O Lebeau; Michael T Stang; Christopher Coyne; Jonas T Johnson; Andrew F Stewart; Yuri E Nikiforov
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

3.  Papillary microcarcinoma of the thyroid gland in renal transplant patients.

Authors:  B Nemes; A Zalatnai; H Podder; J Járay; P Sótonyi; Z Schaff; K Földes; F Perner
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

4.  Clinical efficacy of fine-needle aspiration biopsy of thyroid nodules in males.

Authors:  Adam J Schiro; Scott N Pinchot; Herbert Chen; Rebecca S Sippel
Journal:  J Surg Res       Date:  2009-09-04       Impact factor: 2.192

Review 5.  Controversies in papillary microcarcinoma of the thyroid.

Authors:  Monique Piersanti; Shereen Ezzat; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

Review 6.  Geographic influences in the global rise of thyroid cancer.

Authors:  Jina Kim; Jessica E Gosnell; Sanziana A Roman
Journal:  Nat Rev Endocrinol       Date:  2019-10-15       Impact factor: 43.330

Review 7.  Managing thyroid microcarcinomas.

Authors:  Ernest L Mazzaferri
Journal:  Yonsei Med J       Date:  2012-01       Impact factor: 2.759

8.  Papillary microcarcinomas of the thyroid gland and immunohistochemical analysis of expression of p53 protein in papillary microcarcinomas.

Authors:  Demet Corapcioglu; Serpil D Sak; Tuncay Delibasi; Vedia Tonyukuk; Nuri Kamel; Ali R Uysal; Savas Kocak; Semih Aydintug; Gurbuz Erdogan
Journal:  J Transl Med       Date:  2006-07-05       Impact factor: 5.531

Review 9.  Active surveillance for patients with very low-risk thyroid cancer.

Authors:  Shivangi Lohia; Martin Hanson; R Michael Tuttle; Luc G T Morris
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-02-07

Review 10.  Levothyroxine or minimally invasive therapies for benign thyroid nodules.

Authors:  Elizabeth Bandeira-Echtler; Karla Bergerhoff; Bernd Richter
Journal:  Cochrane Database Syst Rev       Date:  2014-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.